IMUX · Immunic, Inc.

This filing discloses a material leadership transition at Immunic, Inc., centered on CEO Daniel Vitt’s planned succession and functional repositioning. The $670,000 retention agreement—explicitly tied to the hiring of a new CEO with 'deep commercial expertise in the multiple sclerosis space'—confirms the Company is entering a critical inflection point: shifting from clinical development toward commercial execution. Vitt’s proposed transition to a science- and portfolio-focused C-Suite role preserves institutional knowledge but cedes operational and commercial leadership, implying the Board views commercialization readiness—particularly for its MS assets—as the paramount near-term challenge. The 91-day retention period creates a defined window for leadership continuity during search and onboarding, while the acceleration clause (triggered by termination without Cause or resignation for Good Reason) provides downside protection for Vitt but also introduces potential near-term payout risk if transition dynamics deteriorate. Critically, the agreement does not alter Vitt’s existing U.S. or German employment terms, and explicitly states it does not predetermine future separation arrangements—leaving open questions about long-term governance structure, equity treatment, or board oversight post-transition. For investors, this signals both strategic focus and execution risk: successful CEO recruitment is now a key catalyst, and any delay or misstep could impair confidence in the Company’s ability to advance its late-stage pipeline toward market.